Silk Fibroin Nanoadjuvant as a Promising Vaccine Carrier to Deliver the FimH-IutA Antigen for Urinary Tract Infection

Hasanzadeh, Sara; Farokhi, Mehdi; Habibi, Mehri; Shokrgozar, Mohammad Ali; Cohan, Reza Ahangari; Rezaei, Fatemeh; Karam, Mohammad Reza Asadi; Bouzari, Saeid

doi:10.1021/acsbiomaterials.0c00736

Cited by 18 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…100 In preventing urinary tract infections (UTI), the use of SFNPs adjuvant for vaccine delivery validated that their biocompatibility, biodegradability traits, and capability in controlled release of antigen is useful to formulate an efficient vaccine. 101 SFNPs have garnered increased interest in recent times due to their unique properties of tunable size, high surface area to volume ratio, and high drug loading capacity. 102 A suitable adjuvant should be risk-free and should be devoid of negative effects.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

“…Additionally, SF protein has amino acids with amine and carboxyl groups that could facilitate attachment to numerous materials . In preventing urinary tract infections (UTI), the use of SFNPs adjuvant for vaccine delivery validated that their biocompatibility, biodegradability traits, and capability in controlled release of antigen is useful to formulate an efficient vaccine . SFNPs have garnered increased interest in recent times due to their unique properties of tunable size, high surface area to volume ratio, and high drug loading capacity …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation

et al. 2023

View full text Add to dashboard Cite

Adjuvants are the important part of vaccine manufacturing as they elicit the vaccination effect and enhance the durability of the immune response through controlled release. In light of this, nanoadjuvants have shown unique broad spectrum advantages. As nanoparticles (NPs) based vaccines are fast-acting and better in terms of safety and usability parameters as compared to traditional vaccines, they have attracted the attention of researchers. A vaccine nanocarrier is another interesting and promising area for the development of next-generation vaccines for prophylaxis. This review looks at the various nanoadjuvants and their structure−function relationships. It compiles the state-of-art literature on numerous nanoadjuvants to help domain researchers orient their understanding and extend their endeavors in vaccines research and development.

show abstract

Section: ■ Results and Discussionmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The adjuvant properties and sustained release of encapsulated agents make SFNPs promising vaccine adjuvants. [12,13] The size, shape, and surface charge of nanoparticles can impact their interaction with immune cells. [21,22] It has been established that DCs prefer to uptake small-sized particles (20-200 nm), while macrophages take up larger particles.…”

Section: Discussionmentioning

confidence: 99%

Immunogenic Potential and Therapeutic Efficacy of Multi‐Epitope Encapsulated Silk Fibroin Nanoparticles against Pseudomonas aeruginosa‐Mediated Urinary Tract Infections

Rezvanirad

Habibi

Farokhi

et al. 2023

Macromolecular Bioscience

Self Cite

View full text Add to dashboard Cite

Pseudomonas aeruginosa (P. aeruginosa) causing urinary tract infections (UTIs) are a major concern among hospital‐acquired infections. The need for an effective vaccine that reduces the infections is imperative. This study aims to evaluate the efficacy of a multi‐epitope vaccine encapsulated in silk fibroin nanoparticles (SFNPs) against P. aeruginosa‐mediated UTIs. A multi‐epitope is constructed from nine proteins of P. aeruginosa using immunoinformatic analysis, expressed, and purified in BL21 (DE3) cells. The encapsulation efficiency of the multi‐epitope in SFNPs is 85% with a mean particle size of 130 nm and 24% of the encapsulated antigen is released after 35 days. The vaccine formulations adjuvanted with SFNPs or alum significantly improve systemic and mucosal humoral responses and the cytokine profile (IFN‐γ, IL‐4, and IL‐17) in mice. Additionally, the longevity of the IgG response is maintained for at least 110 days in a steady state. In a bladder challenge, mice treated with the multi‐epitope admixed with alum or encapsulated in SFNPs demonstrate significant protection of the bladder and kidneys against P. aeruginosa. This study highlights the promising therapeutic potential of a multi‐epitope vaccine encapsulated in SFNPs or adjuvanted with alum against P. aeruginosa infections.

show abstract

“…Many vaccines designed against individual-specific uropathogens are currently in the stage of basic or clinical trials ( 193 – 195 ). For UPEC bladder infection, there are vaccines targeting type 1 fimbriae, hemolysins, siderophore receptors, cytotoxic necrotizing factor 1 (CNF1), and LPS ( 194 , 196 – 198 ). For P.mirabilis bladder infection, there are vaccines targeting MR/P fimbriae and hemolysins ( 199 , 200 ).…”

Section: Potential Individual Immunomodulatory Interventionsmentioning

confidence: 99%

The immune responses to different Uropathogens call individual interventions for bladder infection

Yang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Urinary tract infection (UTI) caused by uropathogens is the most common infectious disease and significantly affects all aspects of the quality of life of the patients. However, uropathogens are increasingly becoming antibiotic-resistant, which threatens the only effective treatment option available-antibiotic, resulting in higher medical costs, prolonged hospital stays, and increased mortality. Currently, people are turning their attention to the immune responses, hoping to find effective immunotherapeutic interventions which can be alternatives to the overuse of antibiotic drugs. Bladder infections are caused by the main nine uropathogens and the bladder executes different immune responses depending on the type of uropathogens. It is essential to understand the immune responses to diverse uropathogens in bladder infection for guiding the design and development of immunotherapeutic interventions. This review firstly sorts out and comparatively analyzes the immune responses to the main nine uropathogens in bladder infection, and summarizes their similarities and differences. Based on these immune responses, we innovatively propose that different microbial bladder infections should adopt corresponding immunomodulatory interventions, and the same immunomodulatory intervention can also be applied to diverse microbial infections if they share the same effective therapeutic targets.

show abstract

Silk Fibroin Nanoadjuvant as a Promising Vaccine Carrier to Deliver the FimH-IutA Antigen for Urinary Tract Infection

Cited by 18 publications

References 39 publications

Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation

Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation

Immunogenic Potential and Therapeutic Efficacy of Multi‐Epitope Encapsulated Silk Fibroin Nanoparticles against Pseudomonas aeruginosa‐Mediated Urinary Tract Infections

The immune responses to different Uropathogens call individual interventions for bladder infection

Contact Info

Product

Resources

About